ESARTAN AM TAB - Dr Precision is a high-quality, fixed-dose combination antihypertensive tablet expertly formulated with Telmisartan 40 mg, an angiotensin II receptor blocker (ARB), and Amlodipine 5 mg, a calcium channel blocker (CCB). This potent once-daily medication provides effective, sustained blood pressure control through dual mechanisms: Telmisartan blocks the vasoconstrictive effects of angiotensin II, while Amlodipine promotes vasodilation by inhibiting calcium influx into arterial smooth muscle. It is ideal for treating essential hypertension (stages 1 and 2), resistant hypertension, hypertension with left ventricular hypertrophy, and for cardiovascular risk reduction, including post-stroke secondary prevention and management in high-risk hypertensive diabetic patients. Manufactured under rigorous WHO-GMP certified conditions by BluepillExpress and marketed under the Dr Precision label, ESARTAN AM TAB guarantees premium quality, purity, and consistent efficacy. Its once-daily dosing facilitates patient adherence by minimizing pill burden and maintaining stable 24-hour blood pressure control. The product is suited for B2B applications, including private label export, third-party manufacturing, and institutional tender supply, with global regulatory compliance and customizable packaging options for regions such as Asia, Africa, LATAM, CIS, and the Middle East.
Key Features
| Features | Description |
|---|---|
| Combination Components | Telmisartan 40 mg + Amlodipine 5 mg fixed-dose combination |
| Therapeutic Category | Antihypertensive medication targeting essential and resistant hypertension |
| Mechanism of Action | Dual action via angiotensin II receptor blockade (Telmisartan) and calcium channel inhibition (Amlodipine) |
| Dosing | Once-daily oral tablet for sustained 24-hour blood pressure control |
| Indications | Essential hypertension (Stage 1 & 2), resistant hypertension, LVH, cardiovascular risk reduction, post-stroke prevention, high-risk hypertensive diabetics |
| Manufacturing Standards | Produced in WHO-GMP certified facilities under Dr Precision label ensuring quality and compliance |
| Pharmacokinetics | Telmisartan half-life 24 hrs; Amlodipine half-life 30-50 hrs, enabling stable plasma levels |
| Global Market Suitability | Compliance and documentation for export and institutional supply in Asia, Africa, LATAM, CIS, Middle East |
| Packaging | Customizable packaging solutions available for third-party manufacturing and private label |
| Patient Adherence | Simplified regimen reduces pill burden and blood pressure variability |
| Attributes | Description |
|---|---|
| Active Ingredients | Telmisartan 40 mg, Amlodipine 5 mg |
| Formulation | Oral tablet, fixed-dose combination |
| Pharmacological Class | Angiotensin II receptor blocker + Calcium channel blocker |
| Bioavailability | Telmisartan ~50%; Amlodipine 60-65% |
| Half-life | Telmisartan 24 hours; Amlodipine 30–50 hours |
| Metabolism | Telmisartan through hepatic non-CYP pathway; Amlodipine via CYP3A4 hepatic metabolism |
| Excretion | Telmisartan via bile and feces; Amlodipine via urine |
| Indications | Hypertension (essential, resistant), LVH, cardiovascular risk reduction, post-stroke prevention, diabetic hypertension |
| Packaging Options | Customizable packaging for private label export and institutional supply |
| Compliance | WHO-GMP certified manufacturing |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
ESARTAN AM TAB utilizes Telmisartan to block angiotensin II receptors, preventing vasoconstriction and fluid retention, while Amlodipine inhibits calcium influx in vascular smooth muscle causing vasodilation. The synergistic effect targets different pathways of blood pressure regulation, resulting in superior and sustained BP control, reduced cardiovascular risk, and improved patient outcomes versus monotherapy.
Manufactured under stringent WHO-GMP standards by BluepillExpress and branded under Dr Precision, ESARTAN AM TAB ensures consistent quality, purity, and regulatory compliance with robust stability data. Its flexible packaging options and global regulatory documentation facilitate seamless integration into third-party manufacturing, private label branding, and institutional tender supply across multiple international markets.
Yes, ESARTAN AM TAB’s combination of Telmisartan and Amlodipine aids in reducing both blood pressure and cardiac workload. Telmisartan's blockade of the renin-angiotensin system helps prevent cardiac remodeling while Amlodipine reduces systemic vascular resistance, making it ideal for hypertension complicated by LVH.
Telmisartan has a long half-life of approximately 24 hours, and Amlodipine’s half-life ranges between 30 to 50 hours. These properties facilitate sustained plasma concentrations over 24 hours, enabling effective once-daily administration that improves adherence and maintains consistent blood pressure control.
Yes, ESARTAN AM TAB is indicated for high-risk hypertensive diabetic patients due to its ability to manage blood pressure effectively without adversely impacting metabolic parameters, thereby reducing cardiovascular risks associated with diabetes.
Country Of Origin: India
ESARTAN AM TAB is a fixed-dose combination of Telmisartan (40 mg), an angiotensin II receptor blocker (ARB), and Amlodipine (5 mg), a calcium channel blocker (CCB). This powerful once-daily antihypertensive is used for effective blood pressure control, vascular protection, and cardiovascular risk reduction. Manufactured by BluepillExpress, it is ideal for chronic hypertension management in monotherapy or as an add-on in combination regimens. Backed by WHO-GMP compliance and global standards, ESARTAN AM TAB is suitable for third-party manufacturing, private label export, and institutional tender supply.
This product is manufactured under the Dr Precision label, ensuring GMP-compliant quality and precision formulation standards.
ESARTAN AM TAB, manufactured by BluepillExpress, is a dual-action antihypertensive tablet designed to deliver superior and sustained blood pressure control through the synergistic combination of Telmisartan 40 mg and Amlodipine 5 mg. This combination targets hypertension from two critical pathways: renin-angiotensin blockade and vasodilation via calcium channel inhibition.
Telmisartan, a potent ARB (angiotensin II receptor blocker), reduces peripheral vascular resistance by preventing angiotensin II from binding to its receptors, thereby relaxing blood vessels and lowering blood pressure without affecting heart rate. It is known for its long half-life, allowing 24-hour BP control and improved patient adherence.
Amlodipine is a well-established calcium channel blocker that relaxes and widens blood vessels by inhibiting calcium influx into vascular smooth muscle cells. This effect reduces systemic vascular resistance and improves blood flow, contributing significantly to systolic and diastolic pressure reductions.
ESARTAN AM TAB offers a convenient once-daily oral dosing that enhances treatment adherence, reduces pill burden, and minimizes fluctuations in blood pressure throughout the day and night. Its complementary mechanisms make it ideal for patients who do not achieve target BP goals with monotherapy.
The product is manufactured in WHO-GMP certified facilities with a focus on quality, purity, and compliance. With robust stability data, global regulatory documentation, and customizable packaging, ESARTAN AM TAB is ready for export across Asia, Africa, LATAM, CIS, and Middle East regions.
✅ Indications / Therapeutic Uses
Essential Hypertension (Stage 1 & 2)
Resistant Hypertension
Hypertension with left ventricular hypertrophy (LVH)
Cardiovascular risk reduction
Post-stroke secondary prevention (as per physician advice)
High-risk hypertensive diabetic patients
✅ Mechanism of Action
Telmisartan: Blocks the binding of angiotensin II to AT1 receptors, inhibiting vasoconstriction, aldosterone secretion, and sympathetic activation.
Amlodipine: Inhibits L-type calcium channels, leading to vasodilation and reduced peripheral resistance, without negative inotropic effects.
This dual mechanism helps in reducing both systolic and diastolic BP and improves overall cardiovascular hemodynamics.
✅ Pharmacokinetic Highlights
Telmisartan
Oral Bioavailability: ~50%
Half-life: 24 hours
Metabolism: Hepatic (non-CYP dependent)
Excretion: Bile and feces
Amlodipine
Oral Bioavailability: ~60-65%
Half-life: 30–50 hours
Metabolism: Hepatic via CYP3A4
Excretion: Urine
Inclusive of all taxes
You Save: 0
Surat , India
Manufacturer, Contractor, Retailer, Brand Owner, Distributor, Exporter, Importer, Wholesaler, Startup
GST- 24abdfb4194j1ze
